Back to search
FDAFDA · Food and drugs·Recall number Z-0570-2013

BD Phoenix PMIC-108 Panels, Catalog number 448418, labeled in part ***Becton, Dickinson and Company 7 Loveton Circle Sparks, USA. The BD Phoenix" Automated Microbiology system is intended for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically significant bacteria.

Published December 26, 2012 · Recall initiated: November 6, 2012

Summary

FDA records medical device Class II recall Z-0570-2013, published December 26, 2012 and initiated November 6, 2012. Recalling firm: Becton Dickinson & Co.; Status: Terminated; Reported quantity: 12,250 tests; Lot: Lot number 2053373. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

An antibiotic susceptibility test kit may produce false intermediate or false resistant results with clinically significant bacteria.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton Dickinson & Co.
Distributor
Nationwide distribution: USA including states of: AR, CA, KY, OK, RI, WI, and WY.
Lot
Lot number 2053373
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was BD Phoenix PMIC-108 Panels, Catalog number 448418, labeled in part ***Becton, Dickinson and Company 7 Loveton Circle Sparks, USA. The BD Phoenix" Automated Microbiology system is intended for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically significant bacteria. recalled?

Yes. FDA published recall Z-0570-2013 on December 26, 2012. Reported hazard: An antibiotic susceptibility test kit may produce false intermediate or false resistant results with clinically significant bacteria.

What should I do if I have this product?

Voluntary: Firm initiated · Letter